​

Arcus Biosciences (RCUS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RCUS Stock Forecast

Arcus Biosciences (RCUS) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $38.80, with a high of $45.00 and a low of $23.00. This represents a 118.47% increase from the last price of $17.76.

$15 $21 $27 $33 $39 $45 High: $45 Avg: $38.8 Low: $23 Last Closed Price: $17.76

RCUS Stock Rating

Arcus Biosciences stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (83.33%), 3 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 3 15 Strong Sell Sell Hold Buy Strong Buy

RCUS Price Target Upside V Benchmarks

TypeNameUpside
StockArcus Biosciences118.47%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1517
Avg Price Target$41.00$37.80$32.35
Last Closing Price$17.76$17.76$17.76
Upside/Downside130.86%112.84%82.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-112--13
Sep, 26-103--13
Aug, 26-103--13
Jul, 26-103--13
Jun, 26-93--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2026Supawat ThongthipTruist Financial$41.00$23.7572.63%130.86%
Sep 08, 2026Truist Financial$40.00$29.6634.86%125.23%
Aug 10, 2026Morgan Stanley$23.00$28.71-19.89%29.50%
Aug 07, 2026Richard LawGoldman Sachs$42.00$28.3348.25%136.49%
Aug 06, 2026Wedbush$43.00$28.7949.36%142.12%
Jul 20, 2026Emily BodnarH.C. Wainwright$45.00$27.3764.41%153.38%
May 18, 2026Truist Financial$35.00$23.7847.18%97.07%
May 11, 2026Morgan Stanley$22.00$25.32-13.11%23.87%
Apr 20, 2026Leerink Partners$47.00$22.73106.78%164.64%
Feb 12, 2026Wells Fargo$23.00$21.367.68%29.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2026CitigroupBuyBuyhold
Oct 16, 2026William BlairOutperforminitialise
Oct 14, 2026UBSBuyBuyupgrade
Sep 16, 2026Cowen & Co.Buyinitialise
Sep 11, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 07, 2026Goldman SachsBuyBuyhold
Aug 06, 2026WedbushOutperformOutperformhold
Jul 20, 2026H.C. WainwrightBuyBuyhold
Jan 12, 2026Goldman SachsNeutralBuyupgrade
Dec 15, 2025UBSBuyBuyhold

Financial Forecast

EPS Forecast

$-9 $-7 $-5 $-3 $-1 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.76$-3.71$-4.15$-3.14$-3.29---
Avg Forecast$-4.35$-3.88$-4.00$-3.41$-4.33$-4.39$-4.67$-1.29
High Forecast$-2.48$-1.30$-3.89$-2.61$-3.13$-1.95$-2.65$0.11
Low Forecast$-7.76$-8.27$-4.18$-4.16$-5.95$-6.57$-7.29$-3.73
Surprise %-117.47%-4.38%3.75%-7.92%-24.02%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$383.00M$112.00M$117.00M$258.00M$247.00M---
Avg Forecast$40.33M$102.64M$113.67M$246.83M$224.94M$244.84M$260.13M$635.46M
High Forecast$64.67M$191.93M$119.63M$256.90M$484.46M$247.16M$270.13M$1.57B
Low Forecast$27.01M$50.13M$109.48M$233.02M$46.21M$242.52M$250.13M$105.36M
Surprise %849.72%9.12%2.93%4.53%9.80%---

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$53.00M$-267.00M$-307.00M$-283.00M$-353.00M---
Avg Forecast$1.59B$1.43B$-307.00M$-270.00M$-385.92M$-416.98M$-429.11M$-95.16M
High Forecast$1.98B$1.80B$-221.65M$-193.25M$-231.63M$-144.22M$-195.92M$8.04M
Low Forecast$1.20B$1.05B$-392.35M$-307.63M$-440.36M$-485.96M$-539.65M$-276.34M
Surprise %-96.66%-118.73%-4.81%-8.53%---

RCUS Forecast FAQ

Is Arcus Biosciences stock a buy?

Arcus Biosciences stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arcus Biosciences is a favorable investment for most analysts.

What is Arcus Biosciences's price target?

Arcus Biosciences's price target, set by 18 Wall Street analysts, averages $38.8 over the next 12 months. The price target range spans from $23 at the low end to $45 at the high end, suggesting a potential 118.47% change from the previous closing price of $17.76.

How does Arcus Biosciences stock forecast compare to its benchmarks?

Arcus Biosciences's stock forecast shows a 118.47% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Arcus Biosciences over the past three months?

  • October 2026: 0% Strong Buy, 84.62% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 76.92% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 76.92% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.

What is Arcus Biosciences’s EPS forecast?

Arcus Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.39, marking a 33.43% increase from the reported $-3.29 in 2025. Estimates for the following years are $-4.67 in 2027, and $-1.29 in 2028.

What is Arcus Biosciences’s revenue forecast?

Arcus Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $244.84M, reflecting a -0.87% decrease from the reported $247M in 2025. The forecast for 2027 is $260.13M, and $635.46M for 2028.

What is Arcus Biosciences’s net income forecast?

Arcus Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-417M, representing an 18.12% increase from the reported $-353M in 2025. Projections indicate $-429M in 2027, and $-95.164M in 2028.